BioVenture

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Secretech is a research and development-driven biotechnology company focused on creating biomarkers and cellular exosomes. It specializes in developing a molecular detection technology platform designed to offer innovative solutions across scientific, clinical, and drug discovery sectors. The company is dedicated to advancing a new generation of molecular detection methods, integrated with advanced computational biology algorithms. This approach enables Secretech to deliver robust proteomics analysis tools that facilitate the rapid discovery of new molecular markers.

Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.

Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Bioligo, officially known as Shanghai Bailige Biotechnology Co., Ltd., is a biotechnology company specializing in the provision of high-quality DNA synthesis and sequencing services. The company focuses on serving the genetic and molecular diagnostics sector, which is integral to the field of precision medicine. Bioligo offers a range of products, including DNA primers, fluorescently labeled probes, and RNA synthesis products. Additionally, they supply essential materials for next-generation sequencing library construction, such as adapters, blocking agents, and target capture probes. By addressing critical gaps in raw materials, Bioligo supports its downstream customers in the in vitro diagnostic industry, enhancing their capabilities in precision medicine applications.

Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed an innovative neural repair technology that facilitates the conversion of astrocytes into neurons through in vivo methods. By employing adeno-associated virus-based gene therapy to introduce neural transcription factors, NeuExcell aims to enable clinicians to restore damaged neural tissue. The company's mission is to enhance the quality of life for millions of patients worldwide who are affected by neurodegenerative conditions.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

YXgene is a Pharmaceutical company for development of virus vectors, preclinical studies and investigational new drug application

Founded in 2013, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. Its pipeline includes LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and other clinical stage drugs.

Genowise is a company specializing in advanced genetic testing and medical diagnostic services. It offers a range of services, including pharmacogenomics, auxiliary diagnosis, and tumor genome diagnosis. Genowise has developed next-generation gene sequencing reagents and a clinical data analysis system to enhance the effectiveness of genetic testing. The company provides over 15 different genetic testing kits that cover more than 170 diseases and assess over 810 known gene loci, facilitating better health management for patients. Through its innovative approach, Genowise aims to improve diagnostic accuracy and support personalized medicine initiatives.

Admera Health, LLC is a molecular diagnostics company based in South Plainfield, New Jersey, specializing in personalized medicine and non-invasive cancer testing. Founded in 2012, the company operates a laboratory that develops, validates, and delivers proprietary laboratory-developed tests. Admera Health offers a range of services, including PGxOne, a pharmacogenomics test that assesses patient responses to drug therapy based on genetic makeup, and DNA sequencing for analyzing mutations in EGFR and KRAS. Additionally, it provides tests to evaluate risks for inherited health conditions such as high cholesterol and diabetes. The company's product pipeline includes the OncoGxOne cancer panel, which identifies genomic variations related to cancer, and FloraCheck, which analyzes microbiome composition for health management. Utilizing advanced genomic technologies and bioinformatics, Admera Health aims to enhance disease screening, diagnosis, and treatment, ultimately improving health outcomes for patients and supporting healthcare providers and researchers.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.